In this seminar, the very best worldwide ever-reported electrochemical biosensors based on a memristive effect and aptamers or antibodies are presented. These novel sensing nanoscale devices are developed to propose a completely new approach in cancer diagnostics for also applications in stratifying patients toward precision treatments in personalized medicine. To this aim, affinity-based techniques are presented for the detection of the prostate specific antigen (PSA), the Vascular Endothelial Growth Factor (VEGF), and specific drugs like Tenofovir (TFV) as well. The hysteretic properties of memristive silicon nanowires functionalized with proper biomolecules provide a label-free and ultrasensitive bio-detection technique. In order to develop full systems for diagnostics, the integration with CMOS frontend, in one side of the interface, and microfluidics, in the other side, is required too. Therefore, this seminar also proposes and discusses novel circuit approaches for automated and quick characterization of arrays of memristive biosensors. Therefore, the co-design of completely new Bio/Nano/CMOS interfaces for cancer diagnostics based on this new approach is proposed as well. The integration of the readout electronics with nanoscale sensors and microfluidic platform is a must for the design of robust biosensing-systems for quick data acquisition in cancer diagnostics. Therefore, the development of an improved chip-platform for cancer diagnostics based on nanofabricated Memristive Biosensors integrated, for the first time, with a microfluidic structure is also presented in this seminar by also addressing critical issues, e.g., the problems related to long connections between the Memristive Biosensors and the CMOS frontend. Finally, the validation on specimens from tumor extracts from oncological patients is also shown to demonstrate the feasibility of using such a technology for a better stratification of patients for applications in oncology toward personalized medicine.